Detection of neuroblastoma cells during clinical follow up: Advanced flow cytometry and RT-PCR for tyrosine hydroxylase using both conventional and real-time PCR

Klinische Padiatrie

Volumn 223, Issue 6, 2011, Pages 326-331

  Esser, R ^a   Glienke, W ^a   Bochennek, K ^a   Erben, S ^a   Quaiser, A ^a   Pieper, C ^a   Eggert, A ^b   Schramm, A ^b   Astrahantseff, K ^b   Hansmann, M ^a   Schwabe, D ^a   Klingebiel, T ^a   Koehl, U ^a  

^a UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^b UNIVERSITY HOSPITAL ESSEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

TYROSINE 3 MONOOXYGENASE;

ARTICLE; BONE MARROW BIOPSY; CONTROLLED STUDY; DIAGNOSTIC VALUE; EWING SARCOMA; FLOW CYTOMETRY; FOLLOW UP; GANGLIONEUROMA; HODGKIN DISEASE; HUMAN; HUMAN CELL; HUMAN TISSUE; LEUKEMIA; MAJOR CLINICAL STUDY; MINIMAL RESIDUAL DISEASE; NEPHROBLASTOMA; NEUROBLASTOMA; NEUROBLASTOMA CELL; PERIPHERAL BLOOD STEM CELL; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RHABDOMYOSARCOMA;

ACTIVATED-LEUKOCYTE CELL ADHESION MOLECULE; BONE MARROW; CELL LINE, TUMOR; CHILD; DIAGNOSIS, DIFFERENTIAL; FALSE POSITIVE REACTIONS; FLOW CYTOMETRY; FOLLOW-UP STUDIES; GANGLIONEUROMA; GENE EXPRESSION PROFILING; GENETIC MARKERS; HUMANS; NEOPLASM STAGING; NEOPLASM, RESIDUAL; NEOPLASTIC CELLS, CIRCULATING; NEUROBLASTOMA; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TYROSINE 3-MONOOXYGENASE;

EID: 81855228748     PISSN: 03008630     EISSN: 14393824     Source Type: Journal    
DOI: 10.1055/s-0031-1287842     Document Type: Article

References (28)

1. Ambros I M, Brunner B, Aigner G et al. A multilocus technique for risk evaluation of patients with neuroblastoma. Clin Cancer Res 2011; 17: 792-804
2. Ambros P F, Ambros I M, Brodeur G M et al. International consensus for neuroblastoma molecular diagnostics: report from the International Neuroblastoma Risk Group (INRG) Biology Committee. Klin Padiatr 2009; 221: 194
3. Beiske K, Burchill S A, Cheung I Y et al. Consensus criteria for sensitive detection of minimal neuroblastoma cells in bone marrow, blood and stem cell preparations by immunocytology and QRT-PCR: recommendations by the International Neuroblastoma Risk Group Task Force. Br J Cancer 2009; 100: 1627-1637
4. Cai J Y, Tang Y J, Jiang L M et al. Prognostic infl uence of minimal residual disease detected by fl ow cytometry and peripheral blood stem cell transplantation by CD34+ selection in childhood advanced neuroblastoma. Pediatr Blood Cancer 2007; 49: 952-957
5. Campana D. Role of minimal residual disease monitoring in adult and pediatric acute lymphoblastic leukemia. Hematol Oncol Clin North Am 2009; 23: 1083-1098
6. Cheung I Y, Feng Y, Gerald W et al. Exploiting gene expression profi ling to identify novel minimal residual disease markers of neuroblastoma. Clin Cancer Res 2008; 14: 7020-7027
7. Corrias M V, Faulkner L B, Pistorio A et al. Detection of neuroblastoma cells in bone marrow and peripheral blood by diff erent techniques: accuracy and relationship with clinical features of patients. Clin Cancer Res 2004; 10: 7978-7985
8. Csathy L, Kappelmayer J, Szegedi I et al. Classical and atypical neuroblastoma-case reports. Cytometry B Clin Cytom 2011; 80: 134-136
9. Fukuda M, Miyajima Y, Miyashita Y et al. Disease outcome may be predicted by molecular detection of minimal residual disease in bone marrow in advanced neuroblastoma: a pilot study. J Pediatr Hematol Oncol 2001; 23: 10-13
10. Horibe K, Fukuda M, Miyajima Y et al. Outcome prediction by molecular detection of minimal residual disease in bone marrow for advanced neuroblastoma. Med Pediatr Oncol 2001; 36: 203-204
11. Komada Y, Zhang X L, Zhou Y W et al. Flow cytometric analysis of peripheral blood and bone marrow for tumor cells in patients with neuroblastoma. Cancer 1998; 82: 591-599
12. Lambooy L H, Gidding C E, van den Heuvel L P et al. Real-time analysis of tyrosine hydroxylase gene expression: a sensitive and semiquantitative marker for minimal residual disease detection of neuroblastoma. Clin Cancer Res 2003; 9: 812-819
13. Landis J R, Koch G G. An application of hierarchical kappa-type statistics in the assessment of majority agreement among multiple observers. Biometrics 1977; 33: 363-374
14. Marabelle A, Merlin E, Halle P et al. CD34+ immunoselection of autologous grafts for the treatment of high-risk neuroblastoma. Pediatr Blood Cancer 2011; 56: 134-142
15. Matthay K K, Reynolds C P, Seeger R C et al. Long-term results for children with high-risk neuroblastoma treated on a randomized trial of myeloablative therapy followed by 13-cis-retinoic acid: a children's oncology group study. J Clin Oncol 2009; 27: 1007-1013
16. Modak S, Cheung N K. Neuroblastoma: Therapeutic strategies for a clinical enigma. Cancer Treat Rev 2010; 36: 307-317
17. Nagai J, Ishida Y, Koga N et al. A new sensitive and specifi c combination of CD81/CD56/CD45 monoclonal antibodies for detecting circulating neuroblastoma cells in peripheral blood using fl ow cytometry. J Pediatr Hematol Oncol 2000; 22: 20-26
18. Naito H, Kuzumaki N, Uchino J et al. Detection of tyrosine hydroxylase mRNA and minimal neuroblastoma cells by the reverse transcriptionpolymerase chain reaction. Eur J Cancer 1991; 27: 762-765
19. Okcu M F, Wang R Y, Bueso-Ramos C et al. Flow cytometry and fl uorescence in situ hybridization to detect residual neuroblastoma cells in bone marrow. Pediatr Blood Cancer 2005; 45: 787-795
20. Pession A, Libri V, Sartini R et al. Real-time RT-PCR of tyrosine hydroxylase to detect bone marrow involvement in advanced neuroblastoma. Oncol Rep 2003; 10: 357-362
21. Ratei R, Karawajew L, Lacombe F et al. Discriminant function analysis as decision support system for the diagnosis of acute leukemia with a minimal four color screening panel and multiparameter fl ow cytometry immunophenotyping. Leukemia 2007; 21: 1204-1211
22. Stutterheim J, Gerritsen A, Zappeij-Kannegieter L et al. Detecting minimal residual disease in neuroblastoma: the superiority of a panel of real-time quantitative PCR markers. Clin Chem 2009; 55: 1316-1326
23. Stutterheim J, Gerritsen A, Zappeij-Kannegieter L et al. PHOX2B is a novel and specifi c marker for minimal residual disease testing in neuroblastoma. J Clin Oncol 2008; 26: 5443-5449
24. Swerts K, De Moerloose B, Dhooge C et al. Detection of residual neuroblastoma cells in bone marrow: comparison of fl ow cytometry with immunocytochemistry. Cytometry B Clin Cytom 2004; 61: 9-19
25. Trager C, Kogner P, Lindskog M et al. Quantitative analysis of tyrosine hydroxylase mRNA for sensitive detection of neuroblastoma cells in blood and bone marrow. Clin Chem 2003; 49: 104-112
26. Tsang K S, Li C K, Tsoi W C et al. Detection of micrometastasis of neuroblastoma to bone marrow and tumor dissemination to hematopoietic autografts using fl ow cytometry and reverse transcriptase-polymerase chain reaction. Cancer 2003; 97: 2887-2897
27. Viprey V F, Lastowska M A, Corrias M V et al. Minimal disease monitoring by QRT-PCR: guidelines for identifi cation and systematic validation of molecular markers prior to evaluation in prospective clinical trials. J Pathol 2008; 216: 245-252
28. Wehner S, Soerensen J, Schwabe D et al. 10-Parameter fl ow cytometry as a new tool to improve diagnosis and MRD follow-up of acute leukemias. Klin Padiatr 2009; 221: 393-395